Dataset Information


Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation.

ABSTRACT: Radiofrequency ablation (RFA) is an important strategy for treatment of advanced hepatocellular carcinoma (HCC). However, the prognostic indicators of RFA therapy are not known, and there are few strategies for RFA sensitization. The transcription factor sterol regulatory element binding protein 1 (SREBP)-1 regulates fatty-acid synthesis but also promotes the proliferation or metastasis of HCC cells. Here, the clinical importance of SREBP-1 and potential application of knockdown of SREBP-1 expression in RFA of advanced HCC was elucidated. In patients with advanced HCC receiving RFA, a high level of endogenous SREBP-1 expression correlated to poor survival. Inhibition of SREBP-1 activation using a novel small-molecule inhibitor, SI-1, not only inhibited the aerobic glycolysis of HCC cells, it also enhanced the antitumor effects of RFA on xenograft tumors. Overall, our results: (i) revealed the correlation between SREBP-1 and HCC severity; (ii) indicated that inhibition of SREBP-1 activation could be a promising approach for treatment of advanced HCC.

PROVIDER: S-EPMC8660695 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5987756 | BioStudies
| S-EPMC3923023 | BioStudies
| S-EPMC4686130 | BioStudies
| S-EPMC7887603 | BioStudies
| S-EPMC8213545 | BioStudies
| S-EPMC3671035 | BioStudies
2006-01-01 | S-EPMC2131369 | BioStudies
| S-EPMC5447637 | BioStudies
2016-01-01 | S-EPMC4720818 | BioStudies
| S-EPMC5880601 | BioStudies